Alexandra Goll, PhD, nat. Sc.

With more than 30 years of international experience in the pharmaceutical and biotech industry,
I serve as a Board Advisor and certified Non-Executive Board Member (SAIF-NE, Deutsche Börse),
supporting companies in shaping high-level strategic decisions.

Focus areas include:

• Corporate Governance & Supervisory Board Engagement
• IPO Readiness, Capital Market Strategy & M&A
• ESG Integration & Sustainability

Key Roles Throughout My Career:

• Head of Business Development at Calliditas Therapeutics AB,
  responsible for M&A, licensing, and strategic expansion through to the company’s acquisition by Asahi Kasei.
• Managing & General Partner at TVM Capital Life Science,
  raising over €850 million, managing 18 investments and 11 successful exits and IPOs – including Pharmasset, Actelion, Albireo, Idenix, and EUSA.
• Strategic leadership positions at Roche,
  including Global Business Leader HIV/CMV and member of the Roche/Amgen joint Neupogen® launch team.

Today, I advise both publicly listed companies as well as private equity funds, family offices,
and venture capital investors in the life sciences sector – with a strong focus on long-term value creation, strategic positioning, and responsible leadership.

I am currently seeking new Non-Executive Board opportunities with an international scope.